ProPharma’s team of dedicated experts is at the forefront of both existing and emerging industry trends. ProPharma’s team inspires tomorrow by leveraging rich data insights across our service lines and functional areas to develop innovative solutions that answer the most complex needs of both existing and prospective clients.
Quality & Compliance
The Evolving Global Regulatory Landscape As the pharmaceutical industry continues to operate in an increasingly globalized environment, regulatory oversight has evolved into a more interconnected,...
Regulatory Sciences
Navigating Market Access in Eastern Europe The role of the Marketing Authorization Holder (MAH) is central to bringing pharmaceutical products to patients in the European Union and associated...
Quality & Compliance
What challenges are we seeing as life sciences organizations expand AI adoption? Artificial intelligence (AI) is increasingly embedded in compliance areas like medical information, pharmacovigilance,...
Digital Transformation
Our recent LinkedIn poll asked a simple question: What is the first step in a digital transformation journey? The response was decisive. Seventy percent of respondents identified strategy definition...
Full-Service CRO
Clinical trials rarely unravel because of one isolated event. Many continue to progress with underlying issues that gradually impact timelines, data quality, and overall study confidence. A missed...
Regulatory Sciences
FDA's New Quality Management System Regulation Raises the Bar for Inspection Readiness FDA's Quality Management System Regulation (QMSR), which became effective on February 2, 2026, represents one of...
Pharmacovigilance
In the complex landscape of modern pharmacovigilance (PV), the intersection of patient safety and legal litigation poses unique challenges for Marketing Authorization Holders (MAHs). While...
Regulatory Sciences
Developing innovative medicines requires more than scientific excellence. It also requires a regulatory strategy that supports efficient development, aligns with evolving regulatory expectations, and...
Full-Service CRO
Clinical trial timelines are rarely lost during study conduct but are lost long before the first patient is screened. Delays in study startup often begin at country selection and feasibility where...
Quality & Compliance
The FDA's transition from the long-standing Quality System Regulation (QSR, 21 CFR Part 820) to the new Quality Management System Regulation (QMSR) represents one of the most significant regulatory...
Full-Service CRO
Humanized content about engagement strategies with sites and investigators. The Study Start Up (SSU) phase of clinical trials always feels very chaotic when you are in the “thick of it” with...
Regulatory Sciences
In about a week, the committee that advises the FDA on pharmacy compounding will hold a public meeting on several peptides that are popular in sports medicine and do-it-yourself physical...
Regulatory Sciences
The First JCAs Are Revealing More Than a New Process: Early Lessons and JCA Readiness As the first Joint Clinical Assessments (JCAs) moved from planning into practice, a clearer picture is emerging...
Full-Service CRO
Regulatory complexity is unavoidable in global clinical development. The differentiator is not whether organizations face complexity, it is how effectively they operationalize it. Across Europe,...
Full-Service CRO
For years, regulatory readiness was often viewed primarily as a compliance function, an operational necessity required to move clinical studies forward. Today, that perspective is no longer...
Compiling and submitting a New Drug Application (NDA) submission is a complicated and intensive activity. Once you have submitted your application to FDA, you may be curious about what can you expect...
A Safety Data Exchange Agreement (SDEA) or Pharmacovigilance Agreement (PVA) is a legal written contract which ensures that all safety data, PV tasks and responsibilities are detailed between two or...
What is a PSMF? The EU Pharmacovigilance System Master File (PSMF) is a legally required document created and maintained by a Marketing Authorisation Holder (MAH). Essentially, the document is a...
The FDA’s homepage contains an item in the Public Health Focus section from the Office of Communications entitled “Don’t Use Expired Medicine.” Given this mandate, I recall from many years ago the...
The Importance of the eCTD To harmonize the process of regulatory reviews for global drug development, a unified structure was developed and implemented for electronic Common Technical Document...
The term Functional Service Provider (FSP) concept is highly regarded in the field of clinical research. With drug discovery and clinical trials becoming more complex, pharmaceutical firms and...